Immunic Therapeutics' President Jason Tardio credits his start as a primary care sales rep for his success. Daily interactions with clinicians provided a ground-up understanding of customer needs and the business, which became an invaluable foundation for his executive career, challenging the scientist-to-executive narrative.
Jason Tardio's experience as a general manager in South America, where he ran a P&L and rebuilt the business, was a pivotal CEO training ground. This role, managing all functions and driving a turnaround, provided a condensed simulation of the responsibilities of a company's top leader.
Commercialization is not a post-approval task but a parallel track from the start. To succeed, biotech companies must integrate commercial insights into the clinical development program from its earliest stages to ensure trial designs prosecute the drug's differentiation and align with future market needs.
The primary operational difference between biotech and big pharma isn't just budget size, but how resource constraints force radical prioritization. The entire biotech organization must align on three or four critical, needle-moving goals tied to the next financing catalyst, a level of focus often diffused in larger companies.
No launch plan survives contact with the market. The companies and brands that succeed are not those with a flawless initial strategy, but those that can quickly identify what isn't working and rapidly pivot their plans to address real-world market feedback and challenges.
Instead of immediately implementing a new strategy, a new leader's first priority should be conducting in-depth conversations with internal teams, external investors, and patients. Truly listening to these stakeholders is the fastest way to diagnose what's working and what isn't, forming the basis for effective change.
A senior executive's job isn't to be the expert in every function. Their value comes from having broad knowledge ("a mile wide and an inch deep") allowing them to ask the right questions to the functional experts they've hired. Leadership is about expert inquiry, not providing all the answers.
In a growing biotech, the Program Leader is the critical linchpin. This person acts as the "CEO of the asset," responsible for driving the program forward by managing cross-functional teams, often without direct reporting authority. Their ability to lead through influence is invaluable for keeping complex projects on track.